Grafalon

Grafalon is an injectable solution containing anti‑T‑lymphocyte immunoglobulin (rabbit) as the active ingredient. It is supplied as a sterile intravenous preparation for human use and is marketed in the European Union. The product belongs to the class of polyclonal immunoglobulin immunosuppressants and is available only by prescription. Grafalon is administered under the supervision of a qualified healthcare professional and is used in specific transplant-related protocols.

Grafalon is indicated for specific immunosuppressive purposes in transplant medicine.

- Prophylaxis of acute graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation. - Treatment of acute rejection episodes in solid organ transplantation, such as kidney, liver, or heart. - Component of conditioning regimens for certain allogeneic stem cell transplant protocols. - Adjunctive therapy to reduce T‑cell mediated immune responses in selected clinical studies.

The safety profile of Grafalon reflects its immunosuppressive activity, with adverse events ranging from mild to severe.

Common: - Fever, chills, or rigors occurring during or shortly after infusion. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or hypotension during the infusion period. - Mild headache or fatigue that resolves within hours.

Serious: - Severe infections resulting from profound T‑cell depletion. - Cytokine release syndrome presenting with respiratory distress. - Serum‑sickness–like reactions, including rash, arthralgia, and fever. - Hemolytic anemia or thrombocytopenia. - Acute renal impairment associated with immune complex deposition.

Because Grafalon depletes T‑lymphocytes, careful patient assessment and monitoring are required before and during therapy.

- Verify the absence of active infections prior to initiation. - Assess baseline complete blood count and renal function. - Monitor for signs of cytokine release syndrome throughout the infusion. - Use pre‑medication such as antihistamines or corticosteroids as recommended to mitigate infusion reactions. - Avoid use in patients with known hypersensitivity to rabbit proteins. - Consider potential pregnancy risks; use only if the expected benefit outweighs possible fetal harm.

Grafalon may interact with other agents that affect immune function or hemodynamics, requiring dose adjustments or enhanced monitoring.

Avoid: - Concurrent administration of live vaccines, which may cause uncontrolled infection. - Combination with other potent immunosuppressants (e.g., alemtuzumab) without close supervision. - Co‑administration with drugs that significantly lower blood pressure during infusion.

Use with caution: - Concomitant corticosteroids, which may increase infection risk. - Antimicrobial prophylaxis agents, requiring monitoring for additive toxicity. - Anticoagulants, as infusion‑related hypotension can enhance bleeding risk.